In metastatic melanoma, PD-L1 expressed on many exosome surfaces is upregulated by IFN-γ, and concurrently, MAPK mediates cross-resistance in anti-PD-1 treatment (32, 33). The gene discussed is PDCD1; the disease is metastatic melanoma.